Active material: Finasteride
When ATH: G04CB01
CCF: Drug for the treatment of benign prostatic hyperplasia. Ингибитор 5a-редуктазы
ICD-10 codes (testimony): N40
When CSF: 28.01.01.01
Manufacturer: ZENTIVA a.s. (Czech Republic)
Pills, coated light yellow, lenticular.
| 1 tab. | |
| finasteride | 5 mg |
Excipients: lactose monohydrate, corn starch, povidone 30, sodium carboxymethyl starch, sodium docusate, magnesium stearate, gipromelloza 2910/5, macrogol 6000, talc, Titanium dioxide, dimethicone emulsion SE2, iron oxide yellow.
10 PC. – блистеры (3) – пачки картонные.
15 PC. – блистеры (2) – пачки картонные.
Drug for the treatment of benign prostatic hyperplasia. Финастерид – синтетическое 4-азастероидное соединение. Является конкурентным и специфическим ингибитором стероидной 5-альфа редуктазы – внутриклеточного фермента, which converts testosterone to 5-active androgen DHT. Tissue growth and development of prostate benign hyperplasia due to the conversion of testosterone to dihydrotestosterone in the prostate cells. Under the influence of the drug decreases significantly digidrosterona concentration in blood plasma, and in prostate tissue. Finasteride does not bind to androgen receptors.
As a result of the drug decreases the size of the prostate, decreases symptoms, associated with prostatic hyperplasia.
The drug has no effect on the plasma lipid concentration, and the content in plasma cortisol, Estradiol, prolactin, thyroid stimulating hormone, tiroksina.
Absorption and distribution
After oral finasteride is rapidly absorbed from the gastrointestinal tract. Bioavailability is about 80% and independent of food intake. Cmax plasma levels achieved after 1-2 hours after oral administration. Plasma protein binding is about 90%.
Metabolism and excretion
Finasteride is metabolized in the liver and excreted as metabolites in the urine and feces.
Pharmacokinetics in special clinical situations
T1/2 in patients over 60 s is 6 no, in patients over 70 years can be extended to 8 no.
- Benign prostatic hyperplasia (to reduce the size of the prostate, increasing the maximum speed of the flow of urine and reduce symptoms, associated with hyperplasia, reduce the risk of acute urinary retention and the associated probability of surgery).
The drug is prescribed inside of 5 mg 1 time / day, regardless of the meal.
Duration of therapy to assess its effectiveness should be at least 6 Months.
Approximately 50% patients with disappearance of clinical symptoms occurred during the treatment 12 Months.
On the part of the reproductive system: gynecomastia, breast tenderness, impotence, reduced libido and decrease in ejaculate volume.
Other: allergic reactions.
The incidence of side effects than 3-4% and decreases during treatment. In some cases, there is an increased concentration of luteinizing and follicle-stimulating hormone and testosterone (approximately 10%), however, these parameters remained within normal limits.
- Prostate cancer;
- Obstruction of the urinary tract;
- Children's age;
- Hypersensitivity to finasteride and other ingredients.
FROM caution It should appoint a drug in the human liver.
Women of childbearing age and pregnant Avoid contact with the crushed tablets of the drug Penester, tk. the ability of the drug to inhibit the conversion of testosterone to DHT can cause impaired development of the genital organs of male fetus. Penestera tablets film-coated, so, if they are not pulverized or powdered their integrity is not broken, contact with the active material removed.
Before treatment is necessary to eliminate the disease, which may simulate benign prostatic hyperplasia, such as infectious prostatitis, prostate cancer, urethral stricture, hypotension, urinary bladder and a number of changes in the urinary system, occur in some diseases of the nervous system.
Since the use of finasteride, a decrease in prostate-specific antigen (on 41% and 48% according to 6 and 12 Months of therapy), periodically during therapy is necessary to conduct a survey of patients to avoid their prostate cancer.
Currently, cases of drug overdose were reported Penester.
There were no clinically significant drug interactions Penester with other drugs.
The drug is released under the prescription.
No special storage conditions. Shelf life - 3 year.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More